Type 2 Inflammation and Treatment Targets in Atopic Dermatitis
Dermatology NP Lakshee Aldridge explores type 2 inflammation, its role in atopic dermatitis and prurigo nodularis, and how IL-4, IL-13, and IL-31-targeted therapies restore immune balance and improve patient outcomes.
Lakshi Aldredge, NP, is an adult nurse practitioner in the VA Portland Health Care System in Portland, OR.
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of The Dermatologist or HMP Global, their employees, and affiliates.
The APP Institute is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The Derm APP is designed for Advanced Practice Providers who specialize in Dermatology, to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods, while remaining focused on the fundamental principles and terminology associated with dermatology. Engage year-round with The Dermatologist to access clinical insights, interactive features, research news updates, accredited continuing education programs, and more.
